Stryker Corporation 10-Q Summary: Period Ended June 30, 2008
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Stryker Corporation, a leading medical technology company specializing in orthopaedic implants and MedSurg equipment. The report covers the three and six-month periods ended June 30, 2008. The company operates globally with significant sales in both domestic (62% of H1 2008 revenue) and international markets (38% of H1 2008 revenue).
Key Financial Metrics
| Metric | Three Months Ended June 30, 2008 | Six Months Ended June 30, 2008 |
|---|---|---|
| Net Sales | $1,712.6 million | $3,347.0 million |
| Gross Profit | $1,179.4 million (68.9% margin) | $2,313.3 million (69.1% margin) |
| Operating Income | $400.9 million | $784.6 million |
| Net Earnings (Continuing Ops) | $305.8 million | $596.3 million |
| Diluted EPS (Continuing Ops) | $0.73 | $1.43 |
| Cash from Operations | $240.3 million | $431.1 million |
| Cash & Cash Equivalents | $421.6 million (as of June 30, 2008) | |
| Marketable Securities | $2,141.1 million (as of June 30, 2008) | |
| Debt (Current Maturities) | $23.8 million (as of June 30, 2008) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% in Q2 2008 and 16% in the first half of 2008 compared to the same periods in 2007. Growth was driven by increased unit volume, product mix changes, and favorable foreign currency exchange rates.
- Profitability: Net earnings from continuing operations rose 27% in Q2 and 24% in the first half of 2008. This compares favorably to 2007, which included a $19.8 million intangible asset impairment charge in Q2 2007 that did not recur in 2008.
- Segment Performance:
- Orthopaedic Implants: Sales grew 15% in Q2 and 13% in H1. Strong growth was seen in Knee, Trauma, and Spine systems.
- MedSurg Equipment: Sales grew 21% in Q2 and 20% in H1, driven by surgical equipment, endoscopic systems, and patient handling equipment.
- Working Capital: Working capital increased to $4,230.9 million. Days sales in inventory increased to 162 days (from 137 days at year-end 2007) due to inventory buildup for anticipated product launches and currency effects.
Guidance, Outlook, and Risks
- 2008 Outlook: Management projects diluted net earnings per share for 2008 to approximate $2.88, a 22% increase over 2007. Constant currency net sales growth is forecast in the range of 11% to 13%.
- Foreign Currency: Management anticipates a favorable impact on net sales of approximately 2.5% to 3% in Q3 and 3% to 3.5% for the full year if exchange rates hold near June 30 levels.
- Liquidity Risk (Auction-Rate Securities): The company holds $166.8 million in par value of Auction-Rate Securities (ARS). Due to global credit market liquidity issues, auctions for these securities have failed since February 2008. While the company has not recognized an impairment charge and expects to collect interest, these assets are now classified as non-current due to uncertainty regarding liquidation at par value.
- Regulatory and Legal:
- SEC/DOJ Inquiry: The company is cooperating with an informal SEC inquiry and a DOJ subpoena regarding potential Foreign Corrupt Practices Act violations in foreign countries.
- FDA Warning Letters: The company received warning letters in 2007 and 2008 regarding quality system compliance at facilities in Ireland, New Jersey, and Massachusetts. Management is cooperating to address these issues.
- Antitrust: A DOJ grand jury investigation into antitrust violations in the orthopaedic implants industry was closed in 2008.
Investor Verification Checklist
- ARS Liquidity: Verify the status of the $166.8 million in Auction-Rate Securities and the company's ability to access these funds if needed, given the failed auctions.
- Inventory Levels: Monitor the elevated days sales in inventory (162 days) to ensure it aligns with actual product launch schedules and does not indicate obsolescence.
- Regulatory Compliance: Track the resolution of FDA warning letters and the outcome of the DOJ/SEC inquiries regarding foreign sales practices.
- Product Launches: Confirm timelines for the commercialization of new technologies (e.g., FlexiCore, CerviCore, Sightline endoscopes) which are critical to future growth projections.
- Constant Currency Growth: Distinguish between reported sales growth and constant currency growth to assess underlying operational performance versus currency fluctuations.